1.
Indian J Dermatol Venereol Leprol
; 78(3): 408, 2012.
Article
in English
| MEDLINE
| ID: mdl-22565463
Subject(s)
Antineoplastic Agents/adverse effects , Dermatitis, Exfoliative/chemically induced , Drug Eruptions/etiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Piperazines/adverse effects , Pyrimidines/adverse effects , Adult , Benzamides , Dermatitis, Exfoliative/pathology , Drug Eruptions/pathology , Female , Humans , Imatinib Mesylate
2.
Indian J Dermatol Venereol Leprol
; 75(5): 527-8, 2009.
Article
in English
| MEDLINE
| ID: mdl-19736448
3.
Indian J Dermatol Venereol Leprol
; 72(1): 63-4, 2006.
Article
in English
| MEDLINE
| ID: mdl-16481719
Subject(s)
Antineoplastic Agents/adverse effects , Hyperpigmentation/chemically induced , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Nail Diseases/chemically induced , Piperazines/adverse effects , Pyrimidines/adverse effects , Adult , Antineoplastic Agents/therapeutic use , Benzamides , Humans , Imatinib Mesylate , Male , Nails/drug effects , Piperazines/therapeutic use , Pyrimidines/therapeutic use
4.
Indian J Dermatol Venereol Leprol
; 71(1): 45-6, 2005.
Article
in English
| MEDLINE
| ID: mdl-16394363
Subject(s)
Hypopigmentation/chemically induced , Hypopigmentation/epidemiology , Piperazines/adverse effects , Pyrimidines/adverse effects , Benzamides , Biopsy, Needle , Cohort Studies , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/drug therapy , Humans , Hypopigmentation/pathology , Imatinib Mesylate , Immunohistochemistry , Incidence , India/epidemiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Risk Assessment
5.
Indian J Dermatol Venereol Leprol
; 71(4): 287-8, 2005.
Article
in English
| MEDLINE
| ID: mdl-16394444
Subject(s)
Antineoplastic Agents/adverse effects , Lichenoid Eruptions/chemically induced , Myeloproliferative Disorders/drug therapy , Piperazines/adverse effects , Pyrimidines/adverse effects , Antineoplastic Agents/therapeutic use , Benzamides , Follow-Up Studies , Humans , Imatinib Mesylate , Lichenoid Eruptions/physiopathology , Male , Middle Aged , Myeloproliferative Disorders/diagnosis , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Risk Assessment , Severity of Illness Index
6.
Indian J Dermatol Venereol Leprol
; 71(4): 288-9, 2005.
Article
in English
| MEDLINE
| ID: mdl-16394445
Subject(s)
Antineoplastic Agents/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Piperazines/adverse effects , Pyrimidines/adverse effects , Stevens-Johnson Syndrome/chemically induced , Adult , Antineoplastic Agents/therapeutic use , Benzamides , Dose-Response Relationship, Drug , Drug Administration Schedule , Follow-Up Studies , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Male , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Severity of Illness Index , Stevens-Johnson Syndrome/physiopathology
7.
Indian J Dermatol Venereol Leprol
; 71(5): 361-2, 2005.
Article
in English
| MEDLINE
| ID: mdl-16394467